Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Analyst & Investor Meeting
ROCKVILLE, Md.--(BUSINESS WIRE)--Jun 10, 2010 - Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced that its senior management will discuss BENLYSTA and the Phase 3 BLISS trial results during an Analyst & Investor Meeting the Company will host at the 2010 European League Against Rheumatism's Annual European Congress of Rheumatology. The HGSI Analyst & Investor meeting will begin at approximately 9:30 AM Eastern on Thursday, June 17, 2010, and will be accessible by webcast at www.hgsi.com.
Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several days after the live event.
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company's web site at www.hgsi.com.
Contact: Human Genome Sciences, Inc.
Vice President, Corporate Communications
Senior Director, Investor Relations
Posted: June 2010